Complement System

Other Immunology & Inflammation Related Inhibitors

CXCR AhR STING COX IL Receptor gp120/CD4 NOD NADPH-oxidase ROS Nrf2

Cat.No.	Product Name	Information	Product Use Citations
S1322	Dexamethasone	Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.	Blood, August 15 2024, 757-770 Signal Transduct Target Ther, 2025, 10(1):230 Signal Transduct Target Ther, 2025, 10(1):394
S2286	Cyclosporin A	Cyclosporin A, a non-polar cyclic oligopeptide, is an immunosuppressive agent that binds to cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay. Cyclosporin A is generally given following transplant surgery to prevent rejection and has been used to test its toxic effect on a perfused 3D proximal tubule model.Cyclosporin A (NSC 290193) can be used to induce animal models of Chronic Rejection of Liver Transplantation.	Frontiers in Immunology, May 25, 2022, 861292 Circulation Research, March 27, 2026, e327680 Anticancer Research, March 2023, 1103-1112
S8522	Compstatin	Compstatin binds to primates’ complement component C3 and inhibits complement activation with IC50 of 12 μM.	bioRxiv, September 27, 2025, nan Proceedings of the National Academy of Sciences, May 13, 2025, e2412447122 ImmunoHorizons, March 1, 2024, 269-280
S8931	SB290157 trifluoroacetate	SB290157 trifluoroacetate (SB 290157 TFA) is a potent, competitive and selective antagonist of C3a receptor (C3aR) with IC50 of 200 nM for RBL-C3aR.	Advanced Science, October 18, 2024, e2407967 bioRxiv, November 30, 2024, nan Investigative Ophthalmology & Visual Science, May 1, 2025, 2
S0474	Avacopan (CCX168)	Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist.	British Journal of Cancer, 2025, Online ahead of print Br J Cancer, 2025, 10.1038/s41416-025-03185-0 Nature Communications, 2024, 6519
S0803	Danicopan	Danicopan is a potent, selective and orally active inhibitor of factor D with Kd of 0.54 nM for human Factor D. This compound inhibits alternative pathway of complement (APC) activity, and has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).	Scientific Reports, 2024, 18494 iScience, 2023, 108018
S3240	Phaseoloidin	Phaseoloidin, a homogentisic acid glucoside from Nicotiana attenuata trichomes, contributes to the plant's resistance against lepidopteran herbivores. This compound has anti-complement effects.
E1048	JR14a	JR14a, a selective and potent human Complement C3a receptor antagonist, which is assessed by inhibition of intracellular calcium release (IC50=10 nM) induced in human monocyte-derived macrophages by C3a, inhibition of β-hexosaminidase secretion (IC50=8 nM) from human LAD2 mast cells degranulated by C3a, and selectivity for human C3aR over C5aR.
P1269^New	Pegcetacoplan acetate	Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular hemolysis) and downstream MAC formation (intravascular hemolysis).
S3124	Dexamethasone Acetate	Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Acta Pharm Sin B, 2024, 14(8):3528-3542 STAR Protoc, 2023, 4(2):102342 Exp Mol Med, 2022, 54(9):1450-1460
1 2